AUSTIN, Texas, Nov. 7, 2011 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a leading molecular diagnostics company, has been invited to present at the Stephens Fall Investment Conference. The conference will be held at The New York Palace Hotel in New York City on November 15-16, 2011.
Vermillion’s president and CEO, Gail Page, is scheduled to present on Wednesday, November 16, 2011 at 10:30 a.m. Eastern time, with one-on-one meetings held throughout the day. Management will discuss the company’s business plan and objectives for the remainder of 2011.
The presentation will be available via webcast at http://www.wsw.com/webcast/stph17/vrml/. A replay link will also be available for 90 days following the live presentation on the company’s website at www.vermillion.com.
Vermillion continues to see increasing adoption of OVA1® and recently received a notice of allowance for its fifth patent covering a combination of biomarkers associated with Peripheral Artery Disease.
For more information about the conference or to schedule a one-on-one meeting with Vermillion management, contact your Stephens representative.
About Stephens
Founded in 1933, Stephens is a privately-held, independent financial services firm focused on building value for companies, state and local governments, institutions and high-net-worth investors. The company is headquartered in Little Rock, Arkansas, with offices in leading cities across the country. Additional information about Stephens can be found at www.stephens.com.
About Vermillion
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women’s health. Additional information about Vermillion can be found at www.vermillion.com.
SOURCE Vermillion, Inc.
